Fly News Breaks for March 2, 2020
Mar 2, 2020 | 07:57 EDT
Argus analyst Jasper Hellweg raised the firm's price target on Vertex to $270 from $248 and keeps a Buy rating on the shares. The analyst is positive on the company's product line-up and its deep pipeline focused on the cystic fibrosis drugs. Hellweg also cites Vertex's Trikafta becoming its top revenue generator as of Q4 of 2019 after launching in the U.S. and offering treatment to 6K additional patients eligible for the program. Hellweg adds that the treatment is currently under regulatory review in Europe.
News For VRTX From the Last 2 Days
There are no results for your query VRTX